Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Raymond Osarogiagbon, MD, shares practical strategies for clinicians and health systems to boost lung cancer screening rates among eligible patients.

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Raymond Osarogiagbon, MD, highlights the potential benefits of increasing screening rates for patients diagnosed with lung cancer and the broader US health care system.

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a ...

The global lung cancer therapeutics market is on a robust growth trajectory, poised to witness a significant transformation over the next decade. According to recent market projections, the industry ...

Surgery remains the mainstay of treatment for early-stage [non-small cell lung cancer (NSCLC)], regardless of age,” researchers wrote in the Journal of ...

US FDA grants breakthrough device designation to Roche’s companion diagnostic, VENTANA TROP2 (EPR20043) RxDx Device for non-small cell lung cancer: Basel Wednesday, April 30, 20 ...

The first AI-powered companion diagnostic for non-small cell lung cancer has received FDA Breakthrough Device Designation.

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

The device helps identify NSCLC subjects who are likely to benefit from Daiichi Sankyo and AstraZeneca’s Datroway’s treatment ...